

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 27, 2026**

**Apellis Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-38276**  
(Commission  
File Number)

**27-1537290**  
(IRS Employer  
Identification No.)

**100 Fifth Avenue**  
**Waltham, MA**  
(Address of Principal Executive Offices)

**02451**  
(Zip Code)

**Registrant's telephone number, including area code: (617) 977-5700**

**Not applicable**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	APLS	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On February 27, 2026, the Board of Directors (the “Board”) of Apellis Pharmaceuticals, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Mikael Dolsten, M.D., Ph.D., to the Board as a Class I director, effective as of March 1, 2026, to serve until the Annual Meeting of Stockholders to be held in 2027 or until his successor has been duly elected and qualified or until his earlier death, resignation or removal. Dr. Dolsten has not been appointed to serve on any committees of the Board. The Board has determined that Dr. Dolsten is “independent” as contemplated by the Nasdaq Stock Market rules.

Dr. Dolsten will be compensated in the same manner as the Company’s other non-employee directors. Information concerning the current compensation of the Company’s directors for their service on the Board and its committees is set forth in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 23, 2025. Accordingly, upon his election to the Board, Dr. Dolsten was granted under the Company’s 2017 Stock Incentive Plan (i) an option to purchase a number of shares of the Company’s common stock that has a Black-Scholes valuation as of the date of grant equal to \$300,000, as calculated using the same methodology that the Company uses to calculate the value of stock options for the purposes of its financial statements, at an exercise price equal to the closing price of the Company’s common stock on the date of grant, which option will vest with respect to one-third of the shares underlying such option on each of the first, second and third anniversaries of the date of grant, and (ii) restricted stock units (“RSUs”) for a number of shares of the Company’s common stock determined by dividing \$300,000 by the closing price of the Company’s common stock on the date of grant, which RSUs will vest in full on the first anniversary of the date of grant, although Dr. Dolsten may choose to defer vesting of the RSUs until after termination of his service, in each case, subject to Dr. Dolsten’s continued service. In the event of a change in control of the Company, the vesting schedule of the option and the RSUs will accelerate in full.

There are no arrangements or understandings between Dr. Dolsten and any other persons pursuant to which he was elected as a director. Dr. Dolsten has no family relationships with any of the Company’s directors or executive officers. There are no transactions and no proposed transactions between Dr. Dolsten and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Dr. Dolsten has entered into an indemnification agreement with the Company, a form of which was filed as Exhibit 10.7 to the Company’s Registration Statement on Form S-1/A filed with the SEC on October 27, 2017. Pursuant to the terms of this agreement, the Company may be required, among other things, to indemnify Dr. Dolsten for some expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as a director of the Company.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Apellis Pharmaceuticals, Inc.**

Date: March 2, 2026

By: /s/ Timothy Sullivan

Timothy Sullivan  
Chief Financial Officer